Immunoneutralization of endogenousNa/K-ATPase inhibitors in preeclampsia

Although preeclampsia (PE) is a major cause of maternal and fetal mortality, its pathogenesis is not fully understood. Endogenous digitalis-like cardiotonic steroids (CTS) are implicated in the pathophysiology of PE, as illustrated by clinical observations that Digibind, a digoxin antibody which binds CTS, lowers blood pressure in patients with PE. Recently we reported that plasma levels of marinobufagenin (MBG), a bufadienolide vasoconstrictor CTS, are increased four-fold in patients with severe PE. In the present study, we compared levels of MBG in normal and preeclamptic placentae, and tested whether antibodies against MBG, and against ouabain for their interaction with the material purified from preeclamptic placentae via high-performance liquid chromatography (HPLC). Levels of MBG, but not that of endogenous ouabain, exhibited a four-fold elevation in preeclamptic placentae. The elution time of endogenous placental MBG-like immunoreactive material from reverse-phase HPLC column was identical to that of authentic MBG. Immunoassay based on Digibind did not detect cross-reactivity with HPLC containing ouabain-like immunoreactive material, but cross-reacted with HPLC fractions having retention time similar to that of MBG and other bufadienolides. Our results demonstrate that levels of MBG are significantly elevated in preeclamptic placentae, and suggest that MBG is a potential target for immunoneutralization in patients with preeclampsia.

hypertension , preeclampcia

1. МасКау А.Р., Berg C.J., Atrash H.K. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet. Gynecol. 2001;97:533-538.

2.

3. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia. Lancet. 2005; 365: 785-799.

4.

5. Graves S.W. The possible role of digitalislike factors in pregnancy-induced hypertension. Hypertension 1987; 10: 184-186.

6.

7. de Wardener H.E., Clarkson E.M. Concept of natriuretic hormone. Physiol Rev. 1985; 65: 658-759.

8.

9. Blaustein M.P. Physiological effects of endogenous ouabain - control of intracellular Ca-2+ stores and cell responsiveness. Am J Physiol 1993; 264: C1367-C1387.

10.

11. Gallery E.D.M., Hunyor S.M., Gyory A.Z. Plasma volume concentration: a significant factor in both pregnancy-associated hypertension (pre-eclampsia) and chronic hypertension in pregnancy. QJ Med 1979,192: 593-602.

12.

13. Masilamani S., Baylis C. Pregnant rats are refractory to the natriuretic actions of AN P. Am J Physiol. 1994: 267: R1611-R1616.

14.

15. Graves S.W., Valdes R. Jr., Brown B.A., Knight A.B., Craig H.R. Endogenous digoxin-immunoreactive substance in human pregnancies. J Clin Endocrinol Metab. 1984; 58: 748-751.

16.

17. Poston L., Morris J.F., Wolfe C.D., Hilton P.J. Serum digoxin-like substances in pregnancy-induced hypertension. Clin Sci (Lond). 1989; 77: 189-194.

18.

19. Gilson G.J., Graves S.W., Qual ls C.R., Curet L.B. Digoxin-like immunoreactive substance and sodium-potassium-adenosine triphosphatase inhibition in normal pregnancy: a longitudinal study. Obstet Gynecol. 1997; 89: 743-746.

20.

21. Shrivastav P., Gill D.S., D'Souza V., O'Brien P.M., Dandona P. Secretion of atrial natriuretic peptide and digoxin-like immunoreactive substance during pregnancy. Clin Chem. 1988; 34: 977-980.

22.

23. Kaminski K., Rechberger T. Concentration of digoxin-like immunoreactive substance in patients with preeclampsia and its relation to severity of pregnancy-induced hypertension. Am J Obstet Gynecol. 1991: 165: 733-736

24.

25. Ujhelyi M.R., Robert S., Cummings D.M., Colucci R.D., Green P.J., Sailstad J., Vlasses P.H., Zarowitz B.J. Influence of digoxin immune Fab therapy and renal dysfunction on the disposition of total and free digoxin. Ann Intern Med. 1993; 119: 273-277.

26.

27. Yamada K., Goto A., Hui C., Yagi N., Sugimoto T. Effects of the Fab fragment of digoxin antibody on the natriuresis and increase in blood pressure induced by intracerebroventricular infusion of hypertonic saline solution in rats. Clin Sci (Lond). 1992; 82: 625-630

28.

29. Krep H., Price D.A., Soszynski P., Tao Q.F., Graves S.W.,Hollenberg N.K. Volume sensitive hypertension and the digoxin-like factor. Reversal by a Fab directed against digoxin in DOCA-salthypertensive rats. Am J Hypertens. 1995; 8: 921-927.

30.

31. Morris J.F., Poston L., Wolfe C.D., Hilton P.J. A comparison of endogenous digoxin-like immunoreactivity and sodium transport inhibitory activity in umbilical arterial and venous serum. Clin Sci (Lond). 1988; 75: 577-579.

32.

33. Di Grande A., Boura A.L., Read M.A., Malatino L.S., Walters W.A. Release of a substance from the human placenta having digoxin-like immunoreactivity. Clin Exp Pharmacol Physiol. 1993; 20: 603-607.

34.

35. Armler E., Cester N., Salvolini E., Staffolani R., Burkhard M., Mazzanti L., Kotyk A., Romanini С. Human hypertensive placenta contains an increased amount of Na,K-ATPase with higher affinity for cardiac glycosides. Cell Biol Int. 1994; 18: 723-727.

36.

37. Goodlin R.C. Antidigoxin antibodies in eclampsia. New Engl J Med. 1988;318:518-519.

38.

39. Adair C.D, Buckalew V., Taylor K., Ernest J.M., Frye A.H.,Evans C., Veille J.C. Elevated endoxin-like factor complicating amultifetal second trimester pregnancy: treatment with digoxin-binding immunoglobulin. Am J Nephrol. 1996; 16:529-531.

40.

41. Adair D., Hinshaw A., Russell G., Rose J., Veille J., Buckalew V.Effects of Fab digoxin-specific antibodies on mean arterial pressurein severe preeclampsia. Am J Hypertens. 1997; 10: UA.

42.

43. Efficacy study of Digibind for treatment of severepreeclampsia. http://clinicaltrials.gov/show/NCT00158743

44.

45. Ludens J.H., Clark M.A., DuCharme D.W., Harris D.W., Lutzke B.S., Mandel F., Mathews W.R., Sutter D.M., Hamlyn J.M. Purification of an endogenous digitalislike factor from human plasma for structural analysis. Hypertension. 1991; 17: 923-929.

46.

47. Bagrov A.Y., Fedorova O.V., Dmitrieva R.I., Howald W.N., Hunter A.P., Kuznetsova E.A., Shpen V.M. Bufodienolide nature of endogenous inhibitor of Na/K ATPase in the urine from patients with acute myocardial infarction. Hypertension, 1998; 31:1097-1103.

48.

49. Komiyama Y., Dong X.H., Nishimura N., Masaki H., Yoshika M., Masuda M., Takahashi H. A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patients with terminal renal failure. Clin Biochem. 2005; 38: 36-45.

50.

51. Fedorova O.V., Bagrov A.Y. Inhibition of Na/K ATPase from rat aorta by two endogenous Na/K pump inhibitors, ouabain and marinobufagenin. Evidence of interaction with different alpha-subinit isoforms. Am J Hypertens. 1997; 10: 929-935.

52.

53. Fedorova O.V., Lakatta E.G., Bagrov A.Y. Differential effects of acute NaCl loading on endogenous ouabain-like and marinobufagenin-like ligands of the sodium pump in Dahl hypertensive rats. Circulation. 2000; 102: 3009-3014.

54.

55. Gonick H.C., Y Ding, Vaziri N.D., Bagrov A.Y., Fedorova O.V. Simultaneous measurement of marinobufagenin, ouabain and hypertension-associated protein in various disease state. Clin Exp Hypertens 1998; 20 : 617-627.

56.

57. Fridman A.I., Matveev S.A., Agalakova N.I, Fedorova O.V., Lakatta E.G., Bagrov A.Y. Marinobufagenin, an endogenous ligand of а-1 Na/K- ATPase, is a marker of congestive heart failure severity. J Hypertension. 2002; 20: 1189-1194

58.

59. Fedorova O.V., Talan M.I., Agalakova N.I., Lakatta E.G., Bagrov A.Y. An endogenous ligand of a-1 sodium pump, marinobufagenin, is a novel mediator of sodium chloride dependent hypertension. Circulation. 2002; 105:1122-1127.

60.

61. Lopatin D.A., Ailamazian E.K., Dmitrieva R.I., Shpen V.M., Fedorova O.V., Doris .PA., Bagrov A.Y. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J Hypertension. 1999; 17:1179-1187.

62.

63. Averina I.V., Tapilskaya N.I., Reznik V.A., Frolova E.V., Fedorova O.V., Lakatta E.G., Bagrov A.Y. Endogenous Na/K-ATPase inhibitors in patients with preeclampsia. Cell Mol Biol. 2006;52:19-23.

64.

65. Fedorova O.V., Kolodkin N.I., Agalakova N.I., Namikas A.R., Bzhelyansky A., St-Louis J., Lakatta E.G., Bagrov A.Y. Antibody to marinobufagenin lowers blood pressure in pregnant rats on a high NaCl intake. J Hypertens 2005; 23: 835-842.

66.

67. Vu HU, Ianosi-Irimie M.R., Pridjian C.A., Whitbred J.M., Durst J.M., Bagrov A.Y., Fedorova O.V., Pridjian F.G., Puschett J.B. The involvement of marinobufagenin in a rat model of human peeclampsia. Am J Nephrol 2005; 25: 520-528.

68.

69. Mitka M. Vaccine takes aim at hypertension. JAMA. 2007; 298:2854-2855.

70.

71. Waldmann Т.А. Immunotherapy; past, present and future. Nature Medicine 2003; 9: 269-277.

72.

73. Poston L. Endothelial dysfunction in pre-eclampsia. Pharmacol Rep. 2006; 58 Suppl: 69-74.

74.

75. Elareh J., Kennedy D.J., Yashaswi B., Vetteth S., Shidyak A., Kim E.G., Smaili S., Periyasamy S.M., Hariri I.M., Fedorova L., Liu J., Wu L., Kahaleh M.B., Xie Z., Malhotra D., Fedorova O.V., Kashkin V.A., Bagrov A.Y., Shapiro J.I. Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy. Hypertension. 2007; 49: 215-224.

76.

77. Kennedy D.J., Vetteth S., Periyasamy S.M., Kanj M., Fedorova L., Khouri S., Kahaleh M.B., Xie Z., Malhotra D., Kolodkin N.I., Lakatta E.G., Fedorova O.V., Bagrov A.Y., Shapiro J.I. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension. 2006; 47: 488-495.

78.

79. LaMarca H.L., Morris C.A., Pettit G.R., Nagowa T., Puschett J.B. Marinobufagenin impairs first trimester cytotrophoblast differentiation. Placenta. 2006; 7: 984-988.

80.

81. Uddin M.N., Horvat D., Glaser S.S., Danchuk S., Mitchell B.M., Sullivan D.E., Morris C.A., Puschett J.B. Marinobufagenin inhibits proliferation and migration of cytotrophoblast and CHO cells. Placenta. 2008; 29: 266-273.

82.